review

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Authors
Publication date
1 January 2021
Publisher
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      SZTE Publicatio Repozitórium - SZTE - Repository of Publications

      redirect
      oaioai:publicatio.bibl.u-szeged.h...
      Last time updated on 30/10/2025